Sutro Biopharma announced the selected dose from the dose-optimization trial of luveltamab tazevibulin for platinum-resistant ovarian cancer, reporting a 32% objective response rate and a 96% disease control rate in the 5.2 mg/kg group with 25 evaluable patients.